✦ LIBER ✦

Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's Disease psychosis (Acp-103-020)

✍ Scribed by Cummings, J.; Isaacson, S.; Mills, R.; Williams, H.; Chi-Burris, K.; Dhall, R.; Ballard, C.

Book ID: 121340266
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 77 KB
Volume: 333
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2013.07.401

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antipsychotic efficacy and good tolerabi

Antipsychotic efficacy and good tolerability in a Phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020)

✍ Ballard, Clive; Mills, Roger; Williams, Hilde; Chi-Burris, Kathy; Bahr, Daun; Cu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

✍ Gerald G. Krueger; Kim A. Papp; Dow B. Stough; Keith H. Loven; Wayne P. Gulliver 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 480 KB

A phase III, double-blind, placebo-contr

A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2)

✍ W. Sandborn; J.-F. Colombel; R. Enns; B. Feagan; S. Hanauer; I. Lawrance; R. Pan 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Efficacy, safety, and gastrointestinal t

Efficacy, safety, and gastrointestinal tolerability of tapentadol ER in a randomized, double-blind, placebo- and active-controlled phase III study of patients with chronic low back pain

✍ R. Buynak; D. Shapiro; A. Okamoto; C. Lange; M. Etropolski 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 35 KB

Efficacy of piribedil as early combinati

Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study

✍ Marc Ziegler; Alexandre Castro-Caldas; Susanna Del Signore; Olivier Rascol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 775 KB

## Abstract Piribedil is a non‐ergot D2/D3 agonist with a significant antagonist action on α2A and α2C adrenergic receptor subtypes. This double‐blind placebo‐controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's dis

Efficacy, safety, and tolerability of du

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study

✍ Hee Chul Eun; Oh Sang Kwon; Je Ho Yeon; Hyo Seung Shin; Byung Yoon Kim; Byung In 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 555 KB